255 related articles for article (PubMed ID: 25026281)
1. Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells.
Lee YZ; Yang CW; Chang HY; Hsu HY; Chen IS; Chang HS; Lee CH; Lee JC; Kumar CR; Qiu YQ; Chao YS; Lee SJ
Oncotarget; 2014 Aug; 5(15):6087-101. PubMed ID: 25026281
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors.
Yeh TK; Kuo CC; Lee YZ; Ke YY; Chu KF; Hsu HY; Chang HY; Liu YW; Song JS; Yang CW; Lin LM; Sun M; Wu SH; Kuo PC; Shih C; Chen CT; Tsou LK; Lee SJ
J Med Chem; 2017 Jul; 60(13):5599-5612. PubMed ID: 28609101
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.
Li J; Csibi A; Yang S; Hoffman GR; Li C; Zhang E; Yu JJ; Blenis J
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E21-9. PubMed ID: 25524627
[TBL] [Abstract][Full Text] [Related]
4. Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.
Martín-Rufián M; Nascimento-Gomes R; Higuero A; Crisma AR; Campos-Sandoval JA; Gómez-García MC; Cardona C; Cheng T; Lobo C; Segura JA; Alonso FJ; Szeliga M; Albrecht J; Curi R; Márquez J; Colquhoun A; Deberardinis RJ; Matés JM
J Mol Med (Berl); 2014 Mar; 92(3):277-90. PubMed ID: 24276018
[TBL] [Abstract][Full Text] [Related]
5. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma.
Ye X; Zhou Q; Matsumoto Y; Moriyama M; Kageyama S; Komatsu M; Satoh S; Tsuchida M; Saijo Y
Anticancer Res; 2016 Nov; 36(11):6021-6029. PubMed ID: 27793929
[TBL] [Abstract][Full Text] [Related]
7. Opposing roles of glutaminase isoforms in determining glioblastoma cell phenotype.
Szeliga M; Albrecht J
Neurochem Int; 2015 Sep; 88():6-9. PubMed ID: 25529918
[TBL] [Abstract][Full Text] [Related]
8. GLS2 is protumorigenic in breast cancers.
Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
[TBL] [Abstract][Full Text] [Related]
9. Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells.
Szeliga M; Bogacińska-Karaś M; Różycka A; Hilgier W; Marquez J; Albrecht J
Tumour Biol; 2014 Mar; 35(3):1855-62. PubMed ID: 24096582
[TBL] [Abstract][Full Text] [Related]
10. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
[TBL] [Abstract][Full Text] [Related]
11. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis.
Zhang C; Liu J; Zhao Y; Yue X; Zhu Y; Wang X; Wu H; Blanco F; Li S; Bhanot G; Haffty BG; Hu W; Feng Z
Elife; 2016 Jan; 5():e10727. PubMed ID: 26751560
[TBL] [Abstract][Full Text] [Related]
12. Mammalian glutaminase Gls2 gene encodes two functional alternative transcripts by a surrogate promoter usage mechanism.
Martín-Rufián M; Tosina M; Campos-Sandoval JA; Manzanares E; Lobo C; Segura JA; Alonso FJ; Matés JM; Márquez J
PLoS One; 2012; 7(6):e38380. PubMed ID: 22679499
[TBL] [Abstract][Full Text] [Related]
13. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
14. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma.
Yu D; Shi X; Meng G; Chen J; Yan C; Jiang Y; Wei J; Ding Y
Oncotarget; 2015 Apr; 6(10):7619-31. PubMed ID: 25844758
[TBL] [Abstract][Full Text] [Related]
15. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
16. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
17. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway.
Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D
EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042
[TBL] [Abstract][Full Text] [Related]
18. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation.
Csibi A; Lee G; Yoon SO; Tong H; Ilter D; Elia I; Fendt SM; Roberts TM; Blenis J
Curr Biol; 2014 Oct; 24(19):2274-80. PubMed ID: 25220053
[TBL] [Abstract][Full Text] [Related]
19. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
[TBL] [Abstract][Full Text] [Related]
20. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis.
Katt WP; Lukey MJ; Cerione RA
Future Med Chem; 2017 Jan; 9(2):223-243. PubMed ID: 28111979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
